CR20220160A - Derivados de piridazin-3(2h)-ona fusionados con azol - Google Patents

Derivados de piridazin-3(2h)-ona fusionados con azol

Info

Publication number
CR20220160A
CR20220160A CR20220160A CR20220160A CR20220160A CR 20220160 A CR20220160 A CR 20220160A CR 20220160 A CR20220160 A CR 20220160A CR 20220160 A CR20220160 A CR 20220160A CR 20220160 A CR20220160 A CR 20220160A
Authority
CR
Costa Rica
Prior art keywords
azole
derivatives
fused pyridazine
compounds
formula
Prior art date
Application number
CR20220160A
Other languages
English (en)
Inventor
Sean Murphy
Melinda Davis
Scott Olsen
Holly Reichard
Holger Monenschein
Natasha O'rourke
Betty Lam
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CR20220160A publication Critical patent/CR20220160A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se dan a conocer los compuestos de la fórmula 1 y las sales farmacéuticamente aceptables de los mismos, en donde a, ß, n, R4, R5, R6, R7, R8, R9, R10, R11, X1, X2, X3 y X7 se definen en la memoria descriptiva. Esta divulgación también se refiere a los materiales y métodos para la preparación los compuestos de la fórmula 1, a las composiciones farmacéuticas que comprenden los mismos, y a su uso para el tratamiento de las enfermedades, los trastornos y las afecciones asociadas con el GPR139.
CR20220160A 2019-09-16 2020-09-15 Derivados de piridazin-3(2h)-ona fusionados con azol CR20220160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962901052P 2019-09-16 2019-09-16
PCT/US2020/050823 WO2021055326A1 (en) 2019-09-16 2020-09-15 Azole-fused pyridazin-3(2h)-one derivatives

Publications (1)

Publication Number Publication Date
CR20220160A true CR20220160A (es) 2022-06-16

Family

ID=72670806

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220160A CR20220160A (es) 2019-09-16 2020-09-15 Derivados de piridazin-3(2h)-ona fusionados con azol

Country Status (25)

Country Link
US (1) US12370192B2 (es)
EP (1) EP4031552B1 (es)
JP (1) JP7566888B2 (es)
KR (1) KR102924294B1 (es)
CN (1) CN114728975A (es)
AR (1) AR119971A1 (es)
AU (1) AU2020348675B2 (es)
BR (1) BR112022004819A2 (es)
CA (1) CA3150508A1 (es)
CO (1) CO2022004684A2 (es)
CR (1) CR20220160A (es)
DO (1) DOP2022000057A (es)
EC (1) ECSP22020159A (es)
ES (1) ES2997267T3 (es)
HR (1) HRP20250088T1 (es)
HU (1) HUE069908T2 (es)
IL (1) IL291181B2 (es)
JO (1) JOP20220063A1 (es)
MX (1) MX2022003177A (es)
PE (1) PE20221341A1 (es)
PH (1) PH12022550597A1 (es)
PL (1) PL4031552T3 (es)
RS (1) RS66463B1 (es)
TW (1) TWI873185B (es)
WO (1) WO2021055326A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
PE20221341A1 (es) 2019-09-16 2022-09-13 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
JP7697974B2 (ja) 2020-05-08 2025-06-24 武田薬品工業株式会社 Gpr139アゴニストの置換ベンゾトリアジノン代謝物
GB202106872D0 (en) * 2021-05-13 2021-06-30 Addex Pharmaceuticals Sa Novel compounds
CN114149371B (zh) * 2021-11-26 2023-08-22 首都医科大学 四取代吡唑类化合物及其应用
CN116693545A (zh) * 2022-03-01 2023-09-05 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3
CN116063179A (zh) * 2023-02-20 2023-05-05 南京杰运医药科技有限公司 一种4-甲氧基乙酰乙酸甲酯的合成方法
WO2025119351A1 (zh) * 2023-12-08 2025-06-12 深圳湾实验室 Gpr139激动剂
WO2025124544A1 (zh) * 2023-12-14 2025-06-19 华润医药研究院(深圳)有限公司 3,4-二氢-2H-苯并[b][1,4]二氧杂环庚烷类化合物及其制备方法和医药用途
CN120424068A (zh) * 2024-02-02 2025-08-05 上海科技大学 稠杂环类化合物与其制备方法、药物组合物及应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
WO1987004928A1 (fr) 1986-02-24 1987-08-27 Mitsui Petrochemical Industries, Ltd. Agents therapeutiques de la neuropathie
EP0315390B1 (en) 1987-11-04 1994-07-20 Beecham Group Plc Novel 4-oxobenzotriazines and 4-oxoquinazolines
JPH0285851A (ja) 1988-09-22 1990-03-27 Konica Corp 新規な写真用カプラー
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP2874960B2 (ja) 1990-06-03 1999-03-24 コニカ株式会社 新規な染料を含有するハロゲン化銀写真感光材料
JPH04119890A (ja) 1990-09-11 1992-04-21 Konica Corp ピラゾロチアジアジン系色素
JP3430375B2 (ja) 1993-11-12 2003-07-28 コニカ株式会社 感熱転写材料及び該材料に好適な色素
DE4339868A1 (de) * 1993-11-23 1995-05-24 Merck Patent Gmbh Imidazopyridazine
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
DE19704923A1 (de) 1997-02-10 1998-08-13 Hoechst Schering Agrevo Gmbh Klebstoffhaltige Schädlingsbekämpfungsmittel
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
JP2003512422A (ja) 1999-10-29 2003-04-02 メルク シャープ エンド ドーム リミテッド ベンズイミダゾールnmda/nr2bアンタゴニストを使用する疼痛の治療方法
AU5271900A (en) 1999-11-04 2001-05-14 Colorado State University Research Foundation Method and device for attracting insects
FR2801587B1 (fr) 1999-11-30 2002-01-11 Adir Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2002085851A (ja) 2000-09-19 2002-03-26 Totan Information Technology Kk 経済指標予想ゲームシステム
MXPA04003297A (es) 2001-10-10 2004-07-23 Neurosearch As Derivados novedosos de benzotiacina su preparacion y uso.
FR2833955B1 (fr) 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2483515A1 (en) 2002-04-26 2003-11-06 Takeda Pharmaceutical Company Limited Novel thiol derivative, method for producing the same and use thereof
JP4079727B2 (ja) 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体とその製造方法
JP3981316B2 (ja) 2002-09-27 2007-09-26 京セラ株式会社 半導体素子収納用パッケージ
FR2854634B1 (fr) 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1636200A2 (en) 2003-06-09 2006-03-22 Boehringer Ingelheim International GmbH Inhibitors of papilloma virus
US7253164B2 (en) 2003-07-31 2007-08-07 Irm Llc Bicyclic compounds and compositions as PDF inhibitors
FR2865474B1 (fr) 2004-01-26 2008-06-13 Servier Lab Nouveaux derives de benzothiazines fluorees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
FR2879201B1 (fr) 2004-12-10 2007-02-16 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4738988B2 (ja) 2005-11-17 2011-08-03 花王株式会社 2連式吐出器
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
WO2007147208A1 (en) 2006-06-23 2007-12-27 Nufarm Australia Limited Phenoxy alkanoate herbicidal composition and method of preparation and use
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
FR2909090B1 (fr) 2006-11-23 2009-01-09 Sanofi Aventis Sa Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
KR20090082278A (ko) 2006-12-11 2009-07-29 일라이 릴리 앤드 캄파니 Ampa 수용체 강화제
US20080167374A1 (en) 2007-01-09 2008-07-10 Loveland Products, Inc. Pesticide composition and method of use
US8148367B2 (en) 2007-01-12 2012-04-03 Takeda Pharmaceutical Company Limited Renin inhibitors
US20100035918A1 (en) 2007-01-30 2010-02-11 Biogen Idec Ma Inc Imidazolone Compounds and Methods of Making and Using the Same
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
WO2009061699A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
JP2009119088A (ja) 2007-11-16 2009-06-04 Hoya Corp 内視鏡用バイポーラ高周波処置具
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5526040B2 (ja) 2008-02-05 2014-06-18 サノフイ Par1阻害剤としてのトリアゾロピリダジン類、その製造法および薬剤としての使用
JPWO2009119088A1 (ja) 2008-03-25 2011-07-21 武田薬品工業株式会社 複素環化合物
JP2009248543A (ja) 2008-04-11 2009-10-29 Fujifilm Corp 光情報記録媒体および情報記録方法
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
FR2933698A1 (fr) 2008-07-09 2010-01-15 Servier Lab Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN102149407A (zh) * 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
WO2010054067A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2010140339A1 (ja) 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
JPWO2011007756A1 (ja) 2009-07-13 2012-12-27 武田薬品工業株式会社 複素環化合物及びその用途
WO2011036885A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
PE20131116A1 (es) 2010-08-10 2013-10-24 Takeda Pharmaceutical Compuestos heterociclicos potenciadores de ampa
HK1220622A1 (zh) 2013-03-14 2017-05-12 Janssen Pharmaceutica, N.V. Gpr139的生理性配体
CR20170035A (es) 2014-08-06 2017-04-28 Pfizer Compuestos de imidazopiridazina
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
KR20210093886A (ko) 2018-10-18 2021-07-28 에싸 파마 아이엔씨. 안드로겐 수용체 조절제 및 그 사용 방법
WO2020097609A1 (en) 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
WO2020198710A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN114641473A (zh) 2019-09-16 2022-06-17 诺华股份有限公司 Brd9双官能团降解剂及其使用方法
PE20221341A1 (es) 2019-09-16 2022-09-13 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
JP7697974B2 (ja) 2020-05-08 2025-06-24 武田薬品工業株式会社 Gpr139アゴニストの置換ベンゾトリアジノン代謝物
WO2022058791A1 (en) 2020-09-21 2022-03-24 Takeda Pharmaceutical Company Limited Treatment for schizophrenia

Also Published As

Publication number Publication date
HRP20250088T1 (hr) 2025-03-28
IL291181A (en) 2022-05-01
HUE069908T2 (hu) 2025-04-28
CA3150508A1 (en) 2021-03-25
JP7566888B2 (ja) 2024-10-15
BR112022004819A2 (pt) 2022-06-07
WO2021055326A1 (en) 2021-03-25
TWI873185B (zh) 2025-02-21
EP4031552A1 (en) 2022-07-27
PL4031552T3 (pl) 2025-03-17
JOP20220063A1 (ar) 2023-01-30
IL291181B2 (en) 2025-09-01
EP4031552C0 (en) 2024-11-06
CN114728975A (zh) 2022-07-08
ES2997267T3 (en) 2025-02-14
JP2022548602A (ja) 2022-11-21
PH12022550597A1 (en) 2024-03-04
MX2022003177A (es) 2022-04-06
KR102924294B1 (ko) 2026-02-09
ECSP22020159A (es) 2022-05-31
EP4031552B1 (en) 2024-11-06
AR119971A1 (es) 2022-01-26
RS66463B1 (sr) 2025-02-28
KR20220063228A (ko) 2022-05-17
US20230028114A1 (en) 2023-01-26
AU2020348675B2 (en) 2025-11-20
AU2020348675A1 (en) 2022-04-14
DOP2022000057A (es) 2022-06-30
IL291181B1 (en) 2025-05-01
US12370192B2 (en) 2025-07-29
TW202124386A (zh) 2021-07-01
PE20221341A1 (es) 2022-09-13
CO2022004684A2 (es) 2022-07-08

Similar Documents

Publication Publication Date Title
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
ECSP21080966A (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
MX2020009062A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos.
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
UY31068A1 (es) Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570
MX2020007947A (es) Inhibidores de erbb/btk.
MX364527B (es) Derivados de triazolona de piridinilo y piridinilo fusionado.
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
ECSP22082217A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida
CO2024014680A2 (es) Derivados de n-(pirrolidin-3-il o piperidin-4-il)acetamida
ECSP22082219A (es) Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina
CO2022015823A2 (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
CO2025011205A2 (es) Derivados de 1-amino-4-fenilftalazina útiles para el tratamiento de enfermedades neurodegenerativas
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
CO2025010159A2 (es) Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
UY35945A (es) Derivados de azaindol
DOP2017000138A (es) Derivados de fumagilol
MX2018010008A (es) Derivado de piperidina y sus métodos de uso.
UY28534A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos